National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024

PB 84 of 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 23 October 2024    

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 2—Amendments— Additional designated brands effective from 1 February 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 3—Amendments— Additional designated brands effective from 1 April 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024.

 (2) This instrument may also be cited as PB 84 of 2024.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (table)

Omit:

Schedule 2—Amendments— Additional designated brands effective from 1 February 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Isoleucine 50 of the drug Isoleucine with carbohydrate in the form Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50))

Insert:

Schedule 3—Amendments— Additional designated brands effective from 1 April 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (before table item dealing with the brand GA gel of the drug Amino acid formula with vitamins and minerals without lysine and low in tryptophan in the form Sachets containing oral powder 24 g, 30 (GA gel))

Insert:

2  Section 5 (after table item dealing with the brand Kineret of the drug Anakinra in the form Injection 100 mg in 0.67 mL single use pre-filled syringe)

Insert:

3  Section 5 (after table item dealing with the brand Bicillin L-A of the drug Benzathine benzylpenicillin in the form Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe)

Insert:

4  Section 5 (after table item dealing with the brand Pulmicort Turbuhaler of the drug Budesonide in the form Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses)

Insert:

5  Section 5 (after table item dealing with the brand Triumeq of the drug Dolutegravir with abacavir and lamivudine in the form Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg)

Insert:

6  Section 5 (after table item dealing with the brand Estraderm MX 25 of the drug Estradiol in the form Transdermal patches 750 micrograms (as hemihydrate), 8)

Insert:

7  Section 5 (after table item dealing with the brand Flucil of the drug Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL)

Insert:

8  Section 5 (after table item dealing with the brand Fucidin of the drug Fusidic acid in the form Tablet containing sodium fusidate 250 mg)

Insert:

9  Section 5 (after table item dealing with the brand Isoleucine 50 of the drug Isoleucine with carbohydrate in the form Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)

Insert:

10  Section 5 (after table item dealing with the brand MORPHINE SULFATE 30 mg/1 mL MEDSURGE of the drug Morphine in the form Injection containing morphine sulfate pentahydrate 30 mg in 1 mL)

Insert:

11  Section 5 (after table item dealing with the brand Lipistart of the drug Triglycerides - medium chain, formula in the form Oral powder 400 g (Lipistart))

Insert: